Zoetis (NYSE:ZTS) Stock Unloaded Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on September 04th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on July 17th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.

Zoetis Stock Performance

NYSE ZTS opened at $75.70 on Tuesday. The stock has a market cap of $31.28 billion, a PE ratio of 12.47, a P/E/G ratio of 1.77 and a beta of 0.73. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $155.15. The stock has a fifty day simple moving average of $75.58 and a 200-day simple moving average of $93.26.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the firm earned $1.76 EPS. Zoetis’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current year.

Hedge Funds Weigh In On Zoetis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis in the fourth quarter valued at $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in Zoetis in the 1st quarter valued at about $28,000. Elyxium Wealth LLC purchased a new position in shares of Zoetis in the 4th quarter valued at about $32,000. Root Financial Partners LLC grew its position in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares in the last quarter. Finally, Wellington Grp LLC increased its stake in shares of Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after buying an additional 267 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research analyst reports. Stifel Nicolaus reduced their price target on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research note on Thursday, August 20th. Citigroup dropped their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. BNP Paribas Exane decreased their price target on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 11th. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Finally, Barclays cut their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis presently has an average rating of “Hold” and an average price target of $107.43.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.